Published in Trends Mol Med on September 16, 2010
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett (2011) 1.55
Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med (2011) 1.27
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res (2013) 1.13
Gold nanostructures as a platform for combinational therapy in future cancer therapeutics. Cancers (Basel) (2011) 1.00
The architecture and biological performance of drug-loaded LbL nanoparticles. Biomaterials (2013) 0.96
Quantitative analysis of nanoparticle internalization in mammalian cells by high resolution X-ray microscopy. J Nanobiotechnology (2011) 0.89
Dualities in the analysis of phage DNA packaging motors. Bacteriophage (2012) 0.88
A drug-specific nanocarrier design for efficient anticancer therapy. Nat Commun (2015) 0.87
Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications. Drug Discov Today (2014) 0.86
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
FRET-enabled biological characterization of polymeric micelles. Biomaterials (2014) 0.81
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene (2015) 0.79
Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy. Sci Rep (2017) 0.79
Cytotoxic and antiangiogenic paclitaxel solubilized and permeation-enhanced by natural product nanoparticles. Anticancer Drugs (2015) 0.77
Composite microsphere-functionalized scaffold for the controlled release of small molecules in tissue engineering. J Tissue Eng (2016) 0.76
Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market. J Chem Biol (2012) 0.76
Self-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinoma. Int J Nanomedicine (2016) 0.76
Raspberry-like poly(γ-glutamic acid) hydrogel particles for pH-dependent cell membrane passage and controlled cytosolic delivery of antitumor drugs. Int J Nanomedicine (2016) 0.75
Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo. Int J Nanomedicine (2013) 0.75
Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep (2016) 0.75
A Reactive (1)O2 - Responsive Combined Treatment System of Photodynamic and Chemotherapy for Cancer. Sci Rep (2016) 0.75
Layer-by-Layer Assemblies for Cancer Treatment and Diagnosis. Adv Mater (2015) 0.75
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine (2017) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer (2006) 5.75
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release (2001) 4.81
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett (2006) 3.94
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
The emerging nanomedicine landscape. Nat Biotechnol (2006) 3.60
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev (2005) 3.39
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces (2000) 3.33
A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release (2008) 3.27
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev (2003) 3.19
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res (2004) 2.90
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A (2008) 2.55
Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther (2006) 2.48
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol (2005) 2.34
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine (2006) 2.07
The role of Osteopontin in tumor metastasis. J Surg Res (2004) 2.03
Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine (2008) 1.90
Functionalized micellar systems for cancer targeted drug delivery. Pharm Res (2007) 1.90
Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci (2009) 1.88
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett (2010) 1.85
Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem (2005) 1.82
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol (2003) 1.81
Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett (2008) 1.80
Super pH-sensitive multifunctional polymeric micelle. Nano Lett (2005) 1.75
Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs (1999) 1.67
Development of the polymer micelle carrier system for doxorubicin. J Control Release (2001) 1.64
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res (2006) 1.59
Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci (1994) 1.58
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev (2006) 1.50
Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol (2005) 1.41
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 1.35
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem (2007) 1.34
Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv (2005) 1.32
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg (2005) 1.31
Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol (2000) 1.31
Nanoparticle-induced vascular blockade in human prostate cancer. Blood (2010) 1.30
Poly(L-glutamic acid)--anticancer drug conjugates. Adv Drug Deliv Rev (2002) 1.29
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res (2005) 1.29
Liposomal encapsulated anti-cancer drugs. Anticancer Drugs (2005) 1.29
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine (2009) 1.25
Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull (2006) 1.23
Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol (2006) 1.23
Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells. J Biophotonics (2009) 1.23
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J Med Chem (2003) 1.15
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol (2004) 1.15
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer (2005) 1.12
Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) (2004) 1.07
Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials (2010) 1.06
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv (2008) 1.05
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother (2006) 1.04
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology (2006) 1.01
Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine (2006) 0.98
Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res (1998) 0.98
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm (2008) 0.97
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol (2003) 0.97
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer (1996) 0.97
Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem (2009) 0.95
Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv (2009) 0.91
Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res (2004) 0.91
Preparation and characterization of a magnetic and optical dual-modality molecular probe. Nanotechnology (2010) 0.91
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res (2007) 0.89
Nanoparticles for improved therapeutics and imaging in cancer therapy. Recent Pat Nanotechnol (2010) 0.88
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res (2000) 0.86
The energy landscape of a selective tumor-homing pentapeptide. J Phys Chem B (2008) 0.85
Nanobiosystems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.85
The encapsulation and intracellular delivery of trehalose using a thermally responsive nanocapsule. Nanotechnology (2009) 0.84
Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer (2010) 0.83
Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther (2009) 0.82
Caveolae and cancer. Recent Results Cancer Res (2010) 0.82
Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res (1990) 0.81
Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol (2002) 0.79
Targeting the extracellular signature of metastatic colorectal cancers. Expert Opin Ther Targets (2009) 0.78